Navigation Links
CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
Date:3/15/2012

monary bypass surgery, the plasma concentration of fibrinogen has been reported to decrease by 34 to 42 percent, which can increase the risk of post-operative bleeding. During manufacture, CSL Behring's purified, pasteurized, fibrinogen concentrate undergoes multiple steps to remove potential pathogens, including being heated in aqueous solution at 60 degrees centigrade/140 degrees Fahrenheit for 20 hours. A publication by the World Federation of Hemophilia provides additional perspective on this matter. Fibrinogen concentrate is mostly tolerated without undesirable reactions. In rare cases allergoid-anaphylactoid reactions (like generalized urticaria, rash, fall in blood pressure, dyspnoea), and/or rise in temperature are observed. If allergoid-anaphylactoid reactions occur, the administration of fibrinogen concentrate has to be discontinued immediately (e.g. by interruption of the injection/infusion) and an appropriate treatment has to be initiated. The current medical standards for shock treatment are to be observed. There is a potential risk of thromboembolic episodes (including myocardial infarction and pulmonary embolism) following the administration of human plasma fibrinogen concentrate.

Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens. The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV. Th
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
2. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
3. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
4. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
5. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
6. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
7. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
8. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
9. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
10. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
11. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... LOS ANGELES , Oct. 29, 2014 /PRNewswire/ ... pharmaceutical company devoted to bringing new products to ... 2015. ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
(Date:10/30/2014)... Trust, Inc. (NYSE: BMR ), the ... today announced financial results for the third quarter ... 2014 Highlights Financial and Operating Performance ... representing approximately 657,700 square feet,  contributing to: , ... approximately 219,700 square feet; and , An ...
(Date:10/27/2014)... Oct. 27, 2014 Research and Markets ... Market 2014-2018" report to their offering. ... by a variant of the swine H1N1 virus, known as ... infects nose, throat, and lungs. H1N1 virus is an RNA ... different animal species such as humans, swine, birds, seals, and ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3BioMed Realty Trust Reports Third Quarter 2014 Financial Results 2BioMed Realty Trust Reports Third Quarter 2014 Financial Results 3BioMed Realty Trust Reports Third Quarter 2014 Financial Results 4BioMed Realty Trust Reports Third Quarter 2014 Financial Results 5BioMed Realty Trust Reports Third Quarter 2014 Financial Results 6BioMed Realty Trust Reports Third Quarter 2014 Financial Results 7BioMed Realty Trust Reports Third Quarter 2014 Financial Results 8BioMed Realty Trust Reports Third Quarter 2014 Financial Results 9BioMed Realty Trust Reports Third Quarter 2014 Financial Results 10BioMed Realty Trust Reports Third Quarter 2014 Financial Results 11BioMed Realty Trust Reports Third Quarter 2014 Financial Results 12BioMed Realty Trust Reports Third Quarter 2014 Financial Results 13BioMed Realty Trust Reports Third Quarter 2014 Financial Results 14BioMed Realty Trust Reports Third Quarter 2014 Financial Results 15BioMed Realty Trust Reports Third Quarter 2014 Financial Results 16BioMed Realty Trust Reports Third Quarter 2014 Financial Results 17BioMed Realty Trust Reports Third Quarter 2014 Financial Results 18BioMed Realty Trust Reports Third Quarter 2014 Financial Results 19BioMed Realty Trust Reports Third Quarter 2014 Financial Results 20BioMed Realty Trust Reports Third Quarter 2014 Financial Results 21Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3
... -- Dehaier Medical Systems Ltd. (NASDAQ: ... leader in the development, assembly, marketing and sale of ... the Company will present at the CFA 2012 Cross-Continental ... Purple Mountain Hotel in Shanghai on May 18, 2012. ...
... Medical is pleased to announce that Robert E. Pietrafesa ... Officer. "We,re thrilled to have Rob join ... Belluck, Chairman of the Board at Tegra and General ... Medical. "Tegra is well positioned to serve the growing ...
Cached Medicine Technology:Dehaier Medical to Present at the CFA 2012 Cross-Continental Summit on Investment in Shanghai 2Tegra Medical Announces New President/CEO 2Tegra Medical Announces New President/CEO 3
(Date:10/30/2014)... least 2 years old to be covered by U.S. ... exists other than the general recommendation by national and ... the first six months. , So what do ... motivated researchers at the University at Buffalo School of ... of American infants at 6 months and 12 months ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer of sports ... is currently hosting a sweepstakes on its official Facebook ... to U.S. residents age 18 and over, and will ... winner will then be selected at random from all ... NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba Vasquez views ...
(Date:10/30/2014)... 2014 Don Allred Insurance, a leading ... plans for North Carolina residents, is excited to announce ... Holly Hill Mall. The new branch has been up ... customers through all facets of the insurance selection process ... spokesman Scott Allred couldn’t be happier with the timing ...
(Date:10/30/2014)... October 30, 2014 PreDiabetes Centers ... PreD Store shoppers with a supply of sugardown®, ... to reduce post-meal blood sugar spikes. Learning how to ... an important part of a diabetes prevention plan. , ... receive one complimentary tube of sugardown. The offer expires ...
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter ... hormone therapy to men with prostate cancer who also have ... a heart-related cause, a new study suggests. , , The therapy ... in prostate cancer to reduce levels of male hormones to ... And, in the current research, this hormone therapy was linked ...
Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3
... E taken daily could protect the brain and prevent ... suggests. Scientists in Japan discovered it is possible to ... E. ,They say the supplement is a ... disorders such as Alzheimer's. Taking vitamin supplements could help ...
... According to researchers at the Israel Deaconess Medical Center in ... discover the impact that weight loss can make in decreasing ... people into the first long-term study on how weight loss ... 30 per cent of the population now classified as overweight, ...
... hay fever sufferers. According to a new study in Arizona ... help and not trying to avoid it.// The study has ... as antihistamines with less side effects. ,A team ... gave 120 participants in Arizona and Germany either butterbur extract ...
... have two or more forms of the same chemical ... the isomers, only one generally offers all the therapeutic ... results in smaller dosages with lesser side-effects. ,SUN ... of the anti-ulcerant drug omeprazole - ‘es-omeprazole’ - within ...
... be diagnosed with ovarian cancer every year, and the disease ... percent of all cancers among women. A simple blood test ... stage. Currently, around three-quarters of women with ovarian cancer are ... only about a 20 percent chance// of surviving five years. ...
... that sensible drinking could reduce their risk of suffering a ... a new leaflet, the Stroke Association says small amounts of ... clots blocking arteries - which account for 8 out of ... the blood, so can prevents the formation of clots. It ...
Cached Medicine News:Health News:Herbal treatment not to be sneezed at 2
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The VISULAS 532s combines ease of use, efficiency and safety to provide ophthalmologists with an overall system sharply focused on their requirements. ,The VISULAS 532s is a laser of many talent...
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
... 100 Hue Test including MS-Excel scoring template on ... 100 Hue Test comes boxed in clear acrylic ... potential for test disruption by holding the ... from Richmond Products includes 93 color discs, four ...
Medicine Products: